Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. DIAGNOS Inc.
  6. News
  7. Summary
    ADK   CA2524423068

DIAGNOS INC.

(ADK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

DIAGNOS : to be Featured on CEO Clips on the BNN Bloomberg Channel

09/24/2021 | 09:01am EST

BROSSARD, Quebec, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Company”) (TSX Venture: ADK) (OTCQB: DGNOF) (FRA: 4D4A), a leader in early detection of certain critical health issues, announces it will be featured on CEO Clips on the BNN Bloomberg Channel on September 25th and 26th, 2021.

BTV’s CEO Clips, a series of short video profiles on innovative publicly traded companies across North America, will feature DIAGNOS on the BNN Bloomberg Channel beginning September 25th, Saturday & Sunday, throughout the day and evenings. View link: https://b-tv.com/diagnos-using-ai-to-analyze-the-retina/

Further online distribution through BTV’s CEO Clips includes: Thomson Reuters Terminals, Yahoo Finance, Stockwatch, Bloomberg, Stockhouse.com and BTV’s YouTube channel.

About the BNN Bloomberg Channel and BTV:
BNN Bloomberg is Canada’s only Business News Network reporting on finance and the markets.

BTV-Business Television and CEO Clips produce and create the largest library of issuer videos and campaigns for broadcast on TV and financial sites.

About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

Additional information is available at www.diagnos.com and www.sedar.com.

For further information, please contact:

This press release contains forward-looking information. We cannot guarantee that the forward-looking information mentioned will prove to be accurate, as there may be a significant discrepancy between actual results or future events and those mentioned in this statement. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this press release is expressly covered by this caution.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Contact: info@b-tv.com

Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca

Corporate Communications:
Nancy Massicotte
IR Pro Communications Inc.
Dir: +1 604-507-3377
TF: 1-866-503-3377
Email: nancy@irprocommunications.com

Primary Logo

Source: DIAGNOS Inc.

2021 GlobeNewswire, Inc., source Press Releases - Canada

All news about DIAGNOS INC.
11/23DIAGNOS Starts U.S. Clinical Trial Study For Early Detection And Prevention of Stroke
MT
11/23DIAGNOS : 2021-11-23, DIAGNOS will start a clinical trial study in the USA commencing Dece..
PU
11/23DIAGNOS will start a clinical trial study in the USA commencing December 6th, 2021 for ..
AQ
11/23Diagnos Inc. Announces the Beginning of A Clinical Trial Study with CommonSpirit Health..
CI
10/29DIAGNOS Delivers World Class Results in the MICCAI2021 Contest - GAMMA
AQ
10/28Diagnos Says Delivers World Class Results in MICCAI2021 Contest
MT
10/28DIAGNOS DELIVERS WORLD CLASS RESULTS : Gamma
AQ
10/27DIAGNOS Inc. Reports Earnings Results for the Second Quarter and Six Months Ended Septe..
CI
09/25DIAGNOS : 2021-09-24, DIAGNOS to be Featured on CEO Clips on the BNN Bloomberg Channel &nd..
PU
09/24DIAGNOS INC. : Using Artificial Intelligence to Analyze the Retina, CEO Clip Video
NE
More news
Financials
Sales 2022 0,80 M 0,63 M 0,63 M
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -14,7x
Yield 2022 -
Capitalization 30,4 M 23,8 M 23,7 M
Capi. / Sales 2022 37,9x
Capi. / Sales 2023 3,84x
Nbr of Employees 22
Free-Float 69,4%
Chart DIAGNOS INC.
Duration : Period :
DIAGNOS Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 0,44 CAD
Average target price 1,55 CAD
Spread / Average Target 252%
EPS Revisions
Managers and Directors
André M. Larente President, Chief Executive Officer & Director
Marc-André Massue Chief Financial Officer, Secretary & VP-Finance
Vincent Duhamel Chairman
Reid Maclellan Independent Director
Francis Bellido Independent Director
Sector and Competitors
1st jan.Capi. (M$)
DIAGNOS INC.-25.42%24
MICROSOFT CORPORATION48.63%2 482 063
SEA LIMITED44.72%159 771
ATLASSIAN CORPORATION PLC60.91%95 116
DASSAULT SYSTÈMES SE60.07%78 830
ROBLOX CORPORATION0.00%72 991